Baird raised the firm’s price target on Bio-Techne to $82 from $81 and keeps an Outperform rating on the shares. The firm said results came inline as the company mostly characterized end-market conditions as stable, including China and biopharma. Management embedded gradual end-market recovery assumptions in its initial FY25 outlook.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
Questions or Comments about the article? Write to editor@tipranks.com